Added to YB: 2024-02-13
Pitch date: 2024-02-11
IBRX [bullish]
ImmunityBio, Inc.
+66.45%
current return
Author Info
No bio for this author
Company Info
ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient’s immune system and deliver durable protection against cancer and infectious diseases.
Market Cap
$8.5B
Pitch Price
$4.65
Price Target
N/A
Dividend
N/A
EV/EBITDA
-40.96
P/E
-9.19
EV/Sales
65.83
Sector
Biotechnology
Category
special_situation
ImmunityBio: Buy Low Now Vs. Buy High Later
$IBRX: Anktiva PDUFA 4/23 for bladder cancer; prior CRL was mfg issue not drug; superior to $MRK Keytruda; 32% short interest on low float; major ex-US partner post-approval; trials: lung/pancreatic cancer+vaccines; risks: FDA, trials, dilution; high risk/reward
Read full article (7 min)